iBio prices $50M public offering of pre-funded warrants and Series G/H warrants

iBio, Inc.

Combined offering price $0.699 per unit; gross proceeds ~$50M before underwriting discounts and expenses.
Pre-funded warrants exercisable immediately at $0.001; Series G warrants at $0.70 expire upon trial initiation milestone or 5 years.
Series H warrants expire 4 years after closing; total potential additional proceeds of ~$50M if all warrants exercised for cash.
Net proceeds to advance preclinical cardiometabolic programs IBIO-610 (myostatin/activin A bispecific) and IBIO-600.
Closing expected August 22, 2025; 90-day lock-up on share issuance for company and insiders.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.